Eli Lilly & Co. stock (US5324571083): Shares surge 4.36% on Q1 beat, raised guidance

Eli Lilly & Co. stock jumped 4.36% on May 11, 2026, fueled by Q1 2026 results that beat expectations with 55.5% revenue growth and raised full-year outlook, alongside manufacturing expansion.

Eli Lilly & Co. stock rose 4.36% on May 11, 2026, closing higher amid strong investor reaction to first-quarter 2026 earnings that exceeded expectations, according to TradingKey as of 05/11/2026. The company reported quarterly revenue up 55.5% year-over-year and lifted its full-year revenue guidance, driven by blockbuster GLP-1 drugs like Mounjaro. Barclays also raised its price target to $1,400 from $1,350 while maintaining an Overweight rating, citing reinforced long-term growth, per MarketBeat as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eli Lilly & Co.
• Sector/industry: Pharmaceuticals
• Headquarters/country: United States
• Core markets: US, Europe, global
• Key revenue drivers: GLP-1 drugs, diabetes, obesity treatments
• Home exchange/listing venue: NYSE (LLY)
• Trading currency: USD

Eli Lilly & Co.: core business model

Eli Lilly & Co. develops and markets pharmaceutical products worldwide, with a focus on diabetes, obesity, oncology, immunology, and neuroscience. The company generated quarterly revenue up 55.5% year-over-year as reported in Q1 2026 results published April 30, 2026, per MarketBeat as of 05/12/2026. Its business model relies on innovation in high-demand therapies, particularly GLP-1 receptor agonists like Mounjaro, which recently surpassed Merck’s Keytruda as the world’s best-selling drug.

The firm maintains a net margin of 34.98% and return on equity of 105.77% based on latest quarterly data. Eli Lilly invests heavily in R&D and manufacturing to support growth, including a $4.5 billion expansion in Indiana announced alongside Q1 results, pushing total capex since 2020 over $21 billion, according to TradingKey as of 05/11/2026.

Main revenue and product drivers for Eli Lilly & Co.

Key revenue drivers include Mounjaro and Zepbound in the obesity and diabetes segments, contributing to the 56% year-over-year revenue beat explained by CFO Lucas Montarce in earnings commentary. The company set FY 2026 EPS guidance at $35.50-$37.00, with analysts forecasting $35.80 on average. Volume growth offsets pricing pressures, where realized prices fell 13% overall and 25% outside the US in recent periods.

Recent FDA approvals for Foundayo and Donanemab diversify beyond GLP-1s into oral obesity treatments and Alzheimer’s, though a May 4, 2026, FDA report on liver failure linked to Foundayo caused temporary volatility. Eli Lilly’s payout ratio stands at 24.58%, supporting a recent dividend of $5.20 USD with ex-date May 14, 2026, per Sparkasse as of 05/2026.

Industry trends and competitive position

Eli Lilly leads the GLP-1 market amid booming demand for weight-loss drugs, widening its gap over competitors via manufacturing scale-up. The stock traded at around $986 USD on May 12, 2026, in morning session on NYSE, following the 4.36% gain, per Investing.com as of 05/12/2026. Its EPS of $8.55 in Q1 beat consensus of $6.97 by $1.58, reinforcing momentum status.

Why Eli Lilly & Co. matters for US investors

As a NYSE-listed pharma giant headquartered in the US, Eli Lilly offers exposure to the fast-growing US obesity treatment market, where GLP-1 drugs drive over half of revenue growth. US investors benefit from its dominant position in diabetes and weight management, sectors tied to America’s healthcare spending trends.

Conclusion

Eli Lilly & Co. continues to demonstrate robust growth through Q1 2026 earnings beats, raised guidance, and strategic investments, propelling its stock higher. While pricing pressures and regulatory watches persist, the GLP-1 franchise and pipeline expansions position it strongly in pharma. Investors track upcoming catalysts like dividend ex-date and further FDA updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.